Zim Laboratories Share Price

122.90-1.60 (-1.29%)

Live
As On: 03 Jul, 2026, 01:15 PM IST
As On: 03 Jul, 2026, 01:16 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	-
High	124.50
Low	122.90
Prev Close	124.50
Volume	15,622
VWAP(₹)	124.23

Share Price	Value
Today/Current/Last	122.90123.15
Previous Day	124.50123.10

Zim Laboratories Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Zim Laboratories Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	111.44	110.36	90.75	73.23	110.44
Total Income Growth (%)	0.97	21.60	23.93	-33.69	12.60
Total Expenses	103.18	100.88	87.94	72.36	99.43
Total Expenses Growth (%)	2.28	14.72	21.53	-27.22	10.91
EBIT	8.25	9.48	2.82	0.87	11.02
EBIT Growth (%)	-12.92	236.55	223.08	-92.09	30.59
Profit after Tax (PAT)	3.74	4.40	-0.42	-1.87	4.88
PAT Growth (%)	-14.96	-	-	-138.38	22.09
EBIT Margin (%)	7.41	8.59	3.10	1.19	9.98
Net Profit Margin (%)	3.36	3.98	-0.47	-2.56	4.42
Basic EPS (₹)	0.76	0.90	-0.09	-0.38	1.01

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	109.01	109.52	90.44	72.90	110.07
Total Income Growth (%)	-0.46	21.10	24.05	-33.77	13.29
Total Expenses	101.18	100.16	87.05	71.88	98.51
Total Expenses Growth (%)	1.02	15.06	21.10	-27.03	11.44
EBIT	7.84	9.36	3.39	1.02	11.56
EBIT Growth (%)	-16.27	176.27	231.91	-91.17	31.93
Profit after Tax (PAT)	3.28	4.26	0.12	-1.69	5.42
PAT Growth (%)	-22.94	3,571.55	-	-131.21	24.66
EBIT Margin (%)	7.19	8.55	3.75	1.40	10.50
Net Profit Margin (%)	3.01	3.89	0.13	-2.32	4.92
Basic EPS (₹)	0.67	0.87	0.03	-0.35	1.11

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	385.78	384.82	372.61	404.94	337.83
Total Revenue Growth (%)	0.25	3.28	-7.98	19.87	9.12
Total Expenses	377.57	366.81	348.97	369.59	316.79
Total Expenses Growth (%)	2.93	5.11	-5.58	16.67	7.68
Profit after Tax (PAT)	5.84	12.17	17.25	24.43	14.55
PAT Growth (%)	-52.01	-29.46	-29.42	67.93	98.84
Operating Profit Margin (%)	5.71	7.75	8.31	10.27	8.80
Net Profit Margin (%)	1.55	3.20	4.69	6.13	4.36
Basic EPS (₹)	1.19	2.50	3.54	5.01	8.96

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	381.87	381.26	370.16	402.96	334.00
Total Revenue Growth (%)	0.16	3.00	-8.14	20.65	9.12
Total Expenses	373.47	363.64	347.12	367.04	314.70
Total Expenses Growth (%)	2.70	4.76	-5.43	16.63	7.66
Profit after Tax (PAT)	5.97	11.74	16.76	25.01	13.01
PAT Growth (%)	-49.21	-29.91	-33.00	92.19	131.70
Operating Profit Margin (%)	5.83	7.71	8.19	10.46	8.37
Net Profit Margin (%)	1.61	3.12	4.58	6.30	3.94
Basic EPS (₹)	1.22	2.41	3.44	5.13	8.01

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 3.53% of its operating revenues towards interest expenses and 17.07% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	539.39	472.02	446.82	341.58	341.63
Total Assets Growth (%)	14.27	5.64	30.81	-0.01	5.19
Total Liabilities	243.23	219.79	208.08	141.23	165.92
Total Liabilities Growth (%)	10.67	5.63	47.33	-14.88	1.15
Total Equity	296.15	252.24	238.75	200.35	175.71
Total Equity Growth (%)	17.41	5.65	19.17	14.02	9.31
Current Ratio (x)	1.45	1.39	1.43	1.72	1.45
Total Debt to Equity (x)	0.42	0.44	0.45	0.30	0.29
Contingent Liabilities	21.10	15.72	19.44	31.54	7.91

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	525.20	464.39	442.50	334.87	335.42
Total Assets Growth (%)	13.09	4.95	32.14	-0.16	4.73
Total Liabilities	238.85	219.87	210.55	140.69	165.32
Total Liabilities Growth (%)	8.63	4.43	49.66	-14.90	1.28
Total Equity	286.35	244.51	231.95	194.18	170.11
Total Equity Growth (%)	17.11	5.41	19.45	14.15	8.32
Current Ratio (x)	1.36	1.30	1.34	1.62	1.38
Total Debt to Equity (x)	0.43	0.46	0.46	0.31	0.30
Contingent Liabilities	21.10	15.72	19.44	31.54	7.91

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	49.53	41.15	16.28	37.52	49.21
Net Cash used in Investing Activities	-56.35	-39.93	-73.01	-36.20	-14.57
Net Cash flow from Financing Activities	28.19	-9.10	59.53	0.55	-32.97
Net Cash Flow	23.18	-7.65	3.18	3.00	2.03
Closing Cash & Cash Equivalent	25.12	1.95	9.60	6.42	3.42
Closing Cash & Cash Equivalent Growth (%)	1,190.55	-79.72	49.52	87.72	145.62
Total Debt/ CFO (x)	2.48	2.73	6.53	1.59	1.04

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	47.66	50.60	11.47	35.23	47.03
Net Cash used in Investing Activities	-57.41	-41.31	-71.94	-35.21	-14.42
Net Cash flow from Financing Activities	28.19	-9.10	59.53	0.55	-32.97
Net Cash Flow	18.43	0.19	-0.94	0.57	-0.36
Closing Cash & Cash Equivalent	18.80	0.36	0.17	1.11	0.54
Closing Cash & Cash Equivalent Growth (%)	5,069.33	109.57	-84.37	104.68	-40.02
Total Debt/ CFO (x)	2.58	2.22	9.27	1.69	1.09

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 56.35 cr for investing activities which is an YoY increase of 41.13%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	1.97	4.82	7.22	12.19	8.28
Return on Capital Employed (%)	6.13	9.61	10.63	17.73	14.99
Return on Assets (%)	1.08	2.57	3.85	7.15	4.25
Interest Coverage Ratio (x)	3.14	4.35	6.72	10.47	5.46
Asset Turnover Ratio (x)	0.74	0.83	0.93	1.17	1.00
Price to Earnings (x)	54.95	32.15	27.03	14.45	17.86
Price to Book (x)	1.08	1.55	1.95	1.76	1.48
EV/EBITDA (x)	9.66	10.11	12.06	6.93	6.74
EBITDA Margin (%)	11.05	13.06	12.66	14.65	13.61

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	2.08	4.80	7.22	12.87	7.64
Return on Capital Employed (%)	6.36	9.72	10.67	18.47	14.51
Return on Assets (%)	1.13	2.52	3.78	7.46	3.87
Interest Coverage Ratio (x)	3.10	4.29	6.47	10.33	5.11
Asset Turnover Ratio (x)	0.75	0.83	0.94	1.18	1.01
Price to Earnings (x)	53.76	33.33	27.78	14.12	19.96
Price to Book (x)	1.12	1.60	2.01	1.82	1.53
EV/EBITDA (x)	9.92	10.27	12.75	7.12	7.27
EBITDA Margin (%)	11.05	13.01	12.25	14.53	12.88

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Zim Laboratories	112.63	2.22	1.97	6.13	1.08	-1.59	5.71	1.55	1.19	1.45	0.42	2.48
Wanbury Ltd	15.24	17.01	51.50	27.78	7.37	9.07	11.09	5.09	9.32	1.11	2.92	6.64
Kopran Ltd	36.31	1.76	4.85	7.97	2.83	7.09	6.57	3.77	5.33	1.51	0.29	2.29
Anuh Pharma	19.75	2.30	11.65	15.43	7.36	13.16	7.08	5.31	4.10	2.22	0.00	0.00
Kilitch Drug	22.59	2.46	10.78	13.15	6.59	19.85	18.77	12.52	8.91	1.83	0.32	3.70
Add More

Annual Ratios (%)

Choose from Peers

Praveg Comm
Bafna Pharma
SMS Lifesciences Ind
Albert David
Medicamen Bio

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Zim Laboratories Stock Performance	-1.29	22.89	45.93	73.64	38.82	19.96	0.00
Wanbury Ltd Stock Performance	0.67	11.64	11.75	6.92	-1.08	499.48	180.65
Kopran Ltd Stock Performance	3.08	22.59	26.77	48.95	0.77	30.91	1.23
Anuh Pharma Stock Performance	-0.75	2.36	0.10	7.80	-23.50	0.00	0.00
Kilitch Drug Stock Performance	-4.16	27.03	37.19	25.53	-16.49	80.10	141.47
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	1,62,34,670	30.35 %	-2.90
Pledge	0	0.00 %	0.00
FII	9,481	0.02 %	0.00
DII	59,440	0.12 %	-0.04
Others	3,71,96,720	69.65 %	3.05

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	30.35	33.26	33.26	33.26
Pledge	0.00	0.00	0.00	0.00
FII	0.00	0.02	0.00	0.03
DII	0.00	0.12	0.16	0.16
Mutual Funds	0.00	0.00	0.00	0.00
Others	69.65	66.60	66.58	66.55

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
General Meeting
-
Jun 05, 2026
Board Meeting
Audited Results
May 12, 2026
Board Meeting
Quarterly Results
Feb 05, 2026

Board Meetings

Announced on	Meeting on
May 12, 2026	May 19, 2026
Audited Results
Feb 05, 2026	Feb 11, 2026
Quarterly Results
Jan 16, 2026	Jan 21, 2026
Others
Nov 06, 2025	Nov 12, 2025
Quarterly Results
Jul 31, 2025	Aug 07, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 22, 2019 Sep 19, 2019 5%
Aug 14, 2018 Sep 03, 2018 10%
Bonus
Announced on Ex-Date
Nov 12, 2022 Dec 22, 2022
Bonus Ratio: 2 share(s) for every 1 shares held
Aug 14, 2018 Oct 04, 2018
Bonus Ratio: 1 share(s) for every 1 shares held
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Jun 05, 2026 Jun 29, 2026
-
Jan 23, 2026 Feb 16, 2026
-
Oct 13, 2025 Nov 15, 2025
-
Jun 03, 2025 Jun 27, 2025
-
Jun 06, 2024 Jun 27, 2024
Book closure from Jun 21, 2024 to Jun 27, 2024

Announced on	Ex-Date	Dividend%
May 22, 2019	Sep 19, 2019	5%
Aug 14, 2018	Sep 03, 2018	10%

Announced on	Ex-Date
Nov 12, 2022	Dec 22, 2022
Bonus Ratio: 2 share(s) for every 1 shares held
Aug 14, 2018	Oct 04, 2018
Bonus Ratio: 1 share(s) for every 1 shares held

Announced on	Meeting on
Jun 05, 2026	Jun 29, 2026
-
Jan 23, 2026	Feb 16, 2026
-
Oct 13, 2025	Nov 15, 2025
-
Jun 03, 2025	Jun 27, 2025
-
Jun 06, 2024	Jun 27, 2024
Book closure from Jun 21, 2024 to Jun 27, 2024

About Zim Laboratories

Zim Laboratories Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 666.08 Crore) operating in Pharmaceuticals sector.

Zim Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2026.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 111.44 Crore, up .97 % from last quarter Total Income of Rs 110.36 Crore and up .90 % from last year same quarter Total Income of Rs 110.44 Crore. Company has reported net profit after tax of Rs 3.74 Crore in latest quarter.

The company’s top management includes Dr.Anwar Daud, Mr.Ashok Bhatia, Dr.Kamlesh Shende, Mrs.Kavita Loya, Mr.Padmakar Joshi, Mr.Niraj Dhadiwal, Mr.Prakash Sapkal, Mr.Zulfiquar M Kamal, Mr.Shyam Mohan Patro, Mr.Piyush Nikhade. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-03-2026, the company has a total of 5.35 Crore shares outstanding.

Zim Laboratories Share Price Today is Rs. 122.90. On previous day, the Zim Laboratories Share Price (NSE) closed at Rs. 122.5, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 30.35% of the stake in Zim Laboratories shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Zim Laboratories stocks was 0.02% as compared to 0.02% in Dec 2025 with increase of 0.02%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.12% as compared to 0.12% in Dec 2025 with decrease of 0.04%. Out of the total DII holdings in Zim Laboratories shares 0.0% was held by mutual funds. The rest including public held is 69.51%. Zim Laboratories stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Zim Laboratories Dividend: Ever since 1984, Zim Laboratories dividends has been paid out around 2 times. As on 03 Jul, 2026, 01:15 PM IST, The overall dividend yield for Zim Laboratories stands at 0.0%. The last dividend paid was on September 3, 2018 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 1.09.

Zim Laboratories Bonus: The most recent bonus issue had been in year December 22, 2022 around 3 years ago at 1 : 2 ratio. The first bonus issue was announced in Aug 2018.

Stock Forecast:
After showing 111.44 Cr. of sales and 0.97% of quarterly net profit, there have been multiple ups and downs in the Zim Laboratories stock prices in the past few weeks. For example, Zim Laboratories stock price on 25th of June 2026 was around Rs. 124.9. Zim Laboratories share price now stands at an average of Rs. 122.90. Judging by last week's performance, stock is in down trend.

Zim Laboratories has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Zim Laboratories share.

Historical Prices and Performance:
Zim Laboratories, incorporated in 1984 is a Small Cap company (with a market cap of Rs. 666.08) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Zim Laboratories stock was 1.97%, 4.82%, 7.22%, 12.19% and 8.28% respectively.
The Zim Laboratories share gave a 3 year return of 11.31% as compared to Nifty 50 which gave a return of 25.99%.
Zim Laboratories announced 10.0% final dividend on September 3, 2018.

Key Metrics:
PE Ratio of Zim Laboratories is 113.64
Prices/Sales Ratio of Zim Laboratories is 0.86
Price/Book Ratio of Zim Laboratories is 2.24

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Zim Laboratories, major competitors and peers include Themis Medicare, Wanbury Ltd, Kopran Ltd and Anuh Pharma. As of Dec 2025, the dividend yield of Zim Laboratories stands at 0.0% while Themis Medicare, Wanbury Ltd, Kopran Ltd and Anuh Pharma stand at 0.0%, 0.0%, 1.6% and 1.84% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 113.64 and 2.24 respectively.

Leadership of Zim Laboratories :
Piyush Nikhade is Co. Secretary & Compl. Officer
Shyam Mohan Patro is Chief Financial Officer
Anwar Daud is Chairman & Managing Director
Prakash Sapkal is Director & Head
Niraj Dhadiwal is Director - Business Development
Zulfiquar M Kamal is Director - Finance
Kamlesh Shende is Independent Director
Kavita Loya is Independent Director
Padmakar Joshi is Independent Director
Ashok Bhatia is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Sadoday Gyan (Ground Floor),Opp. NADT, Nelson Square,Nagpur, Maharashtra - 440013

Contact

info@zimlab.in

http://www.zimlab.in

PE Ratio(x)	112.72
EPS - TTM(₹)	1.09
MCap(₹ Cr.)	658.05
MCap Rank	95
PB Ratio(x)	2.25
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	133.90
52W Low(₹)	59.31
MCap/Sales	0.86
Beta(1 Month)	-
BV/Share(₹)	55.36

PE Ratio(x)	112.86
EPS - TTM(₹)	1.09
MCap(₹ Cr.)	658.86
MCap Rank	98
PB Ratio(x)	2.22
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	133.95
52W Low(₹)	59.72
MCap/Sales	0.86
Beta(1 Month)	1.14
BV/Share(₹)	55.36

1 Day	-1.29%
1 Month	13.91%
3 Months	82.16%
1 Year	13.98%
3 Years	7.85%
5 Years	N.A.

1 Day	0.04%
1 Month	17.06%
3 Months	84.72%
1 Year	14.08%
3 Years	8.03%
5 Years	114.61%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Zim Laboratories Share Price

Key Metrics